Treatment Update: Cervical Cancer
In 2021, the U.S. Food and Drug Administration (FDA) approved the immunotherapy pembrolizumab (Keytruda), with or without bevacizumab, for the treatment of recurrent or metastatic cervical cancer with tumors that express a molecular "brake" known as PD‑L1.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer